Bronchiectasis Therapeutics - Pipeline Analysis 2018

Bronchiectasis Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Delivery : 1-2 Working Days
Report Code: LS11178
Available Format:

Bronchiectasis is a condition in which damage to the airways causes them to widen and become flabby and scarred. The airways are tubes that carry air in and out of lungs. Bronchiectasis usually is the result of an infection or other condition that injures the walls of airways or prevents the airways from clearing mucus. In bronchiectasis, the airways slowly lose their ability to clear out mucus. When mucus cannot be cleared, it builds up and creates an environment in which bacteria can grow. This leads to repeated, serious lung infections. Each infection causes more damage to airways. Bronchiectasis can lead to serious health problems, such as respiratory failure, atelectasis, and heart failure. In bronchiectasis, the walls of the bronchi are thickened from long-term inflammation and scarring. As a result of the damage, mucus produced by the cells lining the bronchi does not drain normally. Build-up of mucus can cause infection. A cycle of inflammation and infection can develop, leading to loss of lung function over time. The drug candidates of bronchiectasis pipeline include, but are not limited to, CHF 6333, POL 6014 and Amikacin liposomal inhaled.

Some of the companies having drugs in the bronchiectasis pipeline include Alitair Pharmaceuticals Inc., Bayer AG, Grifols SA and Polyphor Ltd.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.

Place An Order

Single User License

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 3250
Group License

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 4000
Enterprise License

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry